Testing the Safety of CB-5339 in Patients With Cancer

Summary

This phase I trial studies the side effects and best dose of CB-5339 in treating patients with solid tumors that has spread to other places in the body (advanced) or lymphomas. CB-5339 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2020-06-18

Primary completion

2021-07-12

Completion

2021-07-12

Outcome

Outcome not reported

Stopped: “Other - Clinical development of the agent has been discontinued”

Drugs

Indications